{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:21:12Z","timestamp":1787170872115,"version":"build-2736575974"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"DOI":"10.1007\/s10143-025-03418-z","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T05:44:23Z","timestamp":1739943863000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The safety and efficacy of anti-PD-1\/PD-L1 monoclonal antibodies for lung cancer brain metastasis: a systematic review and meta-analysis on brain metastasis"],"prefix":"10.1007","volume":"48","author":[{"given":"Pouria","family":"Delbari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Hussain","family":"Ahmadvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7553-1016","authenticated-orcid":false,"given":"Mohammad Sina","family":"Mirjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8801-1158","authenticated-orcid":false,"given":"Bardia","family":"Hajikarimloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8987-9124","authenticated-orcid":false,"given":"Romina","family":"Hamidi Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5602-3816","authenticated-orcid":false,"given":"Saeed","family":"Kargar-Soleimanabad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8370-2611","authenticated-orcid":false,"given":"Mehrshad","family":"Edalat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0521-8420","authenticated-orcid":false,"given":"Amirmohammad","family":"Bahri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Shahir Eftekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8862-0778","authenticated-orcid":false,"given":"Ibrahim","family":"Mohammadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-6925","authenticated-orcid":false,"given":"Mohammad Amin","family":"Habibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"issue":"14","key":"3418_CR1","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","volume":"22","author":"JS Barnholtz-Sloan","year":"2004","unstructured":"Barnholtz-Sloan JS et al (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22(14):2865\u20132872","journal-title":"J Clin Oncol"},{"issue":"10","key":"3418_CR2","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/cncr.10541","volume":"94","author":"LJ Schouten","year":"2002","unstructured":"Schouten LJ et al (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94(10):2698\u20132705","journal-title":"Cancer"},{"issue":"1","key":"3418_CR3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2004.00.1768","volume":"24","author":"JH Suh","year":"2006","unstructured":"Suh JH et al (2006) Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol 24(1):106\u2013114","journal-title":"J Clin Oncol"},{"issue":"13","key":"3418_CR4","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1200\/JCO.2003.12.122","volume":"21","author":"MP Mehta","year":"2003","unstructured":"Mehta MP et al (2003) Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21(13):2529\u20132536","journal-title":"J Clin Oncol"},{"issue":"1","key":"3418_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0360-3016(80)90195-9","volume":"6","author":"B Borgelt","year":"1980","unstructured":"Borgelt B et al (1980) The palliation of brain metastases: final results of the first two studies by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 6(1):1\u20139","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"3418_CR6","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/annonc\/mds529","volume":"24","author":"YL Wu","year":"2013","unstructured":"Wu YL et al (2013) Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann Oncol 24(4):993\u2013999","journal-title":"Ann Oncol"},{"issue":"9","key":"3418_CR7","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/CAD.0000000000000410","volume":"27","author":"M Hochmair","year":"2016","unstructured":"Hochmair M, Holzer S, Burghuber OC (2016) Complete remissions in afatinib-treated non-small-cell lung cancer patients with symptomatic brain metastases. Anticancer Drugs 27(9):914\u2013915","journal-title":"Anticancer Drugs"},{"issue":"4","key":"3418_CR8","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jtho.2018.01.012","volume":"13","author":"HG Hubbeling","year":"2018","unstructured":"Hubbeling HG et al (2018) Safety of combined PD-1 pathway inhibition and intracranial radiation therapy in non-small cell lung cancer. J Thorac Oncol 13(4):550\u2013558","journal-title":"J Thorac Oncol"},{"key":"3418_CR9","doi-asserted-by":"crossref","unstructured":"Shepard MJ et al (2019) Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study. J Neurosurg, : p. 1\u20138","DOI":"10.1093\/neuros\/nyz310_217"},{"issue":"7","key":"3418_CR10","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jtho.2019.02.009","volume":"14","author":"LEL Hendriks","year":"2019","unstructured":"Hendriks LEL et al (2019) Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors. J Thorac Oncol 14(7):1244\u20131254","journal-title":"J Thorac Oncol"},{"issue":"7","key":"3418_CR11","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","volume":"17","author":"SB Goldberg","year":"2016","unstructured":"Goldberg SB et al (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17(7):976\u2013983","journal-title":"Lancet Oncol"},{"key":"3418_CR12","first-page":"n71","volume":"372","author":"JP Matthew","year":"2021","unstructured":"Matthew JP et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"3418_CR13","doi-asserted-by":"crossref","unstructured":"Deeks JJ et al (2019) Analysing data and undertaking meta-analyses.\u00a0In Cochrane Handbook for Systematic Reviews of Interventions pp 241\u2013284","DOI":"10.1002\/9781119536604.ch10"},{"issue":"01","key":"3418_CR14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4103\/sajc.sajc_111_19","volume":"9","author":"W Abbas","year":"2020","unstructured":"Abbas W et al (2020) The real-world experience with nivolumab in previously treated patients with advanced non-small cell lung cancer from a cancer center in India. South Asian J Cancer 9(01):50\u201352","journal-title":"South Asian J Cancer"},{"issue":"7","key":"3418_CR15","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3390\/cancers14071682","volume":"14","author":"B Bj\u00f8rnhart","year":"2022","unstructured":"Bj\u00f8rnhart B et al (2022) Effect and tolerability of immunotherapy in patients with NSCLC with or without brain metastasis. Cancers 14(7):1682","journal-title":"Cancers"},{"issue":"7","key":"3418_CR16","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/0284186X.2019.1615636","volume":"58","author":"B Bj\u00f8rnhart","year":"2019","unstructured":"Bj\u00f8rnhart B et al (2019) Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study. Acta Oncologica 58(7):953\u2013961","journal-title":"Acta Oncologica"},{"issue":"5","key":"3418_CR17","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s00432-022-04121-y","volume":"149","author":"J Chang","year":"2023","unstructured":"Chang J et al (2023) Programmed cell death 1 pathway inhibitors improve the overall survival of small cell lung cancer patients with brain metastases. J Cancer Res Clin Oncol 149(5):1825\u20131833","journal-title":"J Cancer Res Clin Oncol"},{"key":"3418_CR18","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lungcan.2016.05.031","volume":"98","author":"E Dudnik","year":"2016","unstructured":"Dudnik E et al (2016) Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. Lung Cancer 98:114\u2013117","journal-title":"Lung Cancer"},{"issue":"5","key":"3418_CR19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.cllc.2021.02.001","volume":"22","author":"N Frost","year":"2021","unstructured":"Frost N et al (2021) Pembrolizumab as first-line palliative therapy in PD-L1 overexpressing (\u2265 50%) NSCLC: real-world results with special focus on PS\u2265 2, brain metastases, and steroids. Clin Lung Cancer 22(5):411\u2013422","journal-title":"Clin Lung Cancer"},{"key":"3418_CR20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2018.12.017","volume":"128","author":"SM Gadgeel","year":"2019","unstructured":"Gadgeel SM et al (2019) Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: exploratory analyses of the phase III OAK study. Lung cancer 128:105\u2013112","journal-title":"Lung cancer"},{"key":"3418_CR21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.lungcan.2017.12.008","volume":"116","author":"C Gauvain","year":"2018","unstructured":"Gauvain C et al (2018) Intracerebral efficacy and tolerance of nivolumab in non\u2013small-cell lung cancer patients with brain metastases. Lung Cancer 116:62\u201366","journal-title":"Lung Cancer"},{"issue":"5","key":"3418_CR22","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","volume":"21","author":"SB Goldberg","year":"2020","unstructured":"Goldberg SB et al (2020) Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. The Lancet Oncology 21(5):655\u2013663","journal-title":"The Lancet Oncology"},{"issue":"10","key":"3418_CR23","doi-asserted-by":"crossref","first-page":"S238","DOI":"10.1016\/j.jtho.2016.08.107","volume":"11","author":"JW Goldman","year":"2016","unstructured":"Goldman JW et al (2016) P2.36: nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets): track: immunotherapy. J Thorac Oncol 11(10):S238\u2013S239","journal-title":"J Thorac Oncol"},{"issue":"1","key":"3418_CR24","doi-asserted-by":"crossref","first-page":"18174","DOI":"10.1038\/s41598-021-97566-z","volume":"11","author":"A Lauko","year":"2021","unstructured":"Lauko A et al (2021) Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases. Sci Rep 11(1):18174","journal-title":"Sci Rep"},{"issue":"8","key":"3418_CR25","first-page":"100205","volume":"2","author":"AS Mansfield","year":"2021","unstructured":"Mansfield AS et al (2021) Outcomes with pembrolizumab monotherapy in patients with programmed death-ligand 1\u2013positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001, 010, 024, and 042. JTO Clin Res Rep 2(8):100205","journal-title":"JTO Clin Res Rep"},{"issue":"22","key":"3418_CR26","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1111\/1759-7714.14171","volume":"12","author":"J Sheng","year":"2021","unstructured":"Sheng J et al (2021) Efficacy of PD-1\/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: a real-world retrospective study in China. Thorac Cancer 12(22):3019\u20133031","journal-title":"Thorac Cancer"},{"issue":"12","key":"3418_CR27","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.3390\/cancers12123707","volume":"12","author":"M Skribek","year":"2020","unstructured":"Skribek M et al (2020) Outcome of patients with NSCLC and brain metastases treated with immune checkpoint inhibitors in a \u2018real-life\u2019setting. Cancers 12(12):3707","journal-title":"Cancers"},{"key":"3418_CR28","unstructured":"\u00a0Sun L et al (2020) Outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) with brain metastases treated with pembrolizumab-based therapy. American Society of Clin Oncol"},{"issue":"2","key":"3418_CR29","doi-asserted-by":"crossref","first-page":"e0192227","DOI":"10.1371\/journal.pone.0192227","volume":"13","author":"M Tamiya","year":"2018","unstructured":"Tamiya M et al (2018) Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: a retrospective multicenter trial. PLoS One 13(2):e0192227","journal-title":"PLoS One"},{"key":"3418_CR30","doi-asserted-by":"crossref","unstructured":"Tozuka T et al (2020) Poor efficacy of anti\u2010programmed cell death\u20101\/ligand 1 monotherapy for non\u2010small cell lung cancer patients with active brain metastases. Thorac Cancer 11(9): 2465-2472","DOI":"10.1111\/1759-7714.13557"},{"key":"3418_CR31","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00262-019-02462-1","volume":"69","author":"G Zhang","year":"2020","unstructured":"Zhang G et al (2020) Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study. Cancer Immunol Immunother 69:399\u2013405","journal-title":"Cancer Immunol Immunother"},{"key":"3418_CR32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11060-020-03686-3","volume":"152","author":"M Zhang","year":"2021","unstructured":"Zhang M et al (2021) Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases. J neuro-oncol 152:125\u2013134","journal-title":"J neuro-oncol"},{"issue":"6","key":"3418_CR33","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.21037\/jtd.2018.06.08","volume":"10","author":"MZ Afzal","year":"2018","unstructured":"Afzal MZ, Dragnev K, Shirai K (2018) A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancer. J Thor Dis 10(6):3575","journal-title":"J Thor Dis"},{"issue":"6","key":"3418_CR34","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jtho.2023.01.083","volume":"18","author":"X Hou","year":"2023","unstructured":"Hou X et al (2023) Efficacy, safety, and health-related quality of life with camrelizumab plus pemetrexed and carboplatin as first-line treatment for advanced nonsquamous NSCLC with brain metastases (CAP-BRAIN): a multicenter, open-label, single-arm, phase 2 study. J Thorac Oncol 18(6):769\u2013779","journal-title":"J Thorac Oncol"},{"issue":"28","key":"3418_CR35","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1200\/JCO.22.02561","volume":"41","author":"E Nadal","year":"2023","unstructured":"Nadal E et al (2023) Phase II trial of atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non\u2013small-cell lung cancer with untreated brain metastases (Atezo-Brain, GECP17\/05). J Clin Oncol 41(28):4478","journal-title":"J Clin Oncol"},{"issue":"2","key":"3418_CR36","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jtho.2021.09.014","volume":"17","author":"N Nogami","year":"2022","unstructured":"Nogami N et al (2022) IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain. J Thorac Oncol 17(2):309\u2013323","journal-title":"J Thorac Oncol"},{"issue":"2","key":"3418_CR37","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jtho.2022.10.014","volume":"18","author":"LG Paz-Ares","year":"2023","unstructured":"Paz-Ares LG et al (2023) First-line nivolumab plus ipilimumab with chemotherapy versus chemotherapy alone for metastatic NSCLC in CheckMate 9LA: 3-year clinical update and outcomes in patients with brain metastases or select somatic mutations. J Thorac Oncol 18(2):204\u2013222","journal-title":"J Thorac Oncol"},{"issue":"11","key":"3418_CR38","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.jtho.2021.06.020","volume":"16","author":"SF Powell","year":"2021","unstructured":"Powell SF et al (2021) Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: pooled analysis of KEYNOTE-021,-189, and-407. J Thorac Oncol 16(11):1883\u20131892","journal-title":"J Thorac Oncol"},{"key":"3418_CR39","doi-asserted-by":"crossref","unstructured":"Sun C et al (2020) PD-1\/PD-L1 inhibitor combined with chemotherapy can improve the survival of non-small cell lung cancer patients with brain metastases. OncoTargets and therapy 12777-12786","DOI":"10.2147\/OTT.S286600"},{"issue":"12","key":"3418_CR40","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1007\/s00432-022-04177-w","volume":"148","author":"Y Zhu","year":"2022","unstructured":"Zhu Y et al (2022) PD-1 inhibitors plus chemotherapy in EGFR\/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR\/ALK-TKIs therapy. J Cancer Res Clin Oncol 148(12):3557\u20133566","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"3418_CR41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00262-022-03232-2","volume":"72","author":"R Descourt","year":"2023","unstructured":"Descourt R et al (2023) First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score\u2265 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study). Cancer Immunol Immunother 72(1):91\u201399","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"3418_CR42","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/CJI.0000000000000340","volume":"43","author":"G Metro","year":"2020","unstructured":"Metro G et al (2020) Efficacy of pembrolizumab monotherapy in patients with or without brain metastases from advanced non\u2013small cell lung cancer with a PD-L1 Expression\u2265 50%. J Immunother 43(9):299\u2013306","journal-title":"J Immunother"},{"key":"3418_CR43","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1007\/s12094-021-02588-8","volume":"23","author":"G Metro","year":"2021","unstructured":"Metro G et al (2021) Upfront pembrolizumab as an effective treatment start in patients with PD-L1\u2265 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis. Clin Transl Oncol 23:1818\u20131826","journal-title":"Clin Transl Oncol"},{"key":"3418_CR44","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2020.11.009","volume":"151","author":"K Wakuda","year":"2021","unstructured":"Wakuda K et al (2021) Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression. Lung Cancer 151:60\u201368","journal-title":"Lung Cancer"},{"issue":"2","key":"3418_CR45","doi-asserted-by":"crossref","first-page":"312","DOI":"10.21037\/tlcr-23-83","volume":"12","author":"Q Wang","year":"2023","unstructured":"Wang Q et al (2023) Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer\u2014a retrospective cohort study. Transl Lung Cancer Res 12(2):312","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"3418_CR46","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jtho.2020.10.089","volume":"16","author":"A Juloori","year":"2021","unstructured":"Juloori A et al (2021) RO01.01 prospective evaluation of ipilimumab and nivolumab in patients with non-small cell lung cancer brain metastasis. J Thorac Oncol 16(1):S45","journal-title":"J Thorac Oncol"},{"issue":"4","key":"3418_CR47","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S1556-0864(23)00264-2","volume":"18","author":"S Kilickap","year":"2023","unstructured":"Kilickap S et al (2023) 10MO EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients (pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1)\u2265 50%\u20143-year update. J Thorac Oncol 18(4):S42\u2013S43","journal-title":"J Thorac Oncol"},{"issue":"8","key":"3418_CR48","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jtho.2023.04.021","volume":"18","author":"M Reck","year":"2023","unstructured":"Reck M et al (2023) Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic NSCLC and baseline brain metastases from CheckMate 227 part 1. J Thorac Oncol 18(8):1055\u20131069","journal-title":"J Thorac Oncol"},{"issue":"176","key":"3418_CR49","doi-asserted-by":"crossref","first-page":"321","DOI":"10.24976\/Discov.Med.202335176.33","volume":"35","author":"J-Q Song","year":"2023","unstructured":"Song J-Q et al (2023) Efficacy of PD-1 inhibitors combined with anti-angiogenic therapy in driver gene mutation negative non-small-cell lung cancer with brain metastases. Discovery medicine 35(176):321\u2013331","journal-title":"Discovery medicine"},{"issue":"1","key":"3418_CR50","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40164-023-00412-3","volume":"12","author":"H Wang","year":"2023","unstructured":"Wang H et al (2023) Outcome differences between PD-1\/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases. Exp Hematol Oncol 12(1):56","journal-title":"Exp Hematol Oncol"},{"key":"3418_CR51","doi-asserted-by":"crossref","first-page":"628124","DOI":"10.3389\/fonc.2021.628124","volume":"11","author":"P Wang","year":"2021","unstructured":"Wang P et al (2021) Efficacy and safety of anti-PD-1 plus anlotinib in patients with advanced non\u2013small-cell lung cancer after previous systemic treatment failure\u2014a retrospective study. Front Oncol 11:628124","journal-title":"Front Oncol"},{"key":"3418_CR52","doi-asserted-by":"crossref","unstructured":"Yang X et al (2022) Efficacy of PD-1\/PD-L1 Inhibitors versus chemotherapy in lung cancer with brain metastases: a systematic review and meta-analysis. J Immunol Res 4518898","DOI":"10.1155\/2022\/4518898"},{"key":"3418_CR53","doi-asserted-by":"crossref","first-page":"875093","DOI":"10.3389\/fimmu.2022.875093","volume":"13","author":"G Huo","year":"2022","unstructured":"Huo G, Liu W, Chen P (2022) Inhibitors of PD-1 in non-small cell lung cancer: a meta-analysis of clinical and molecular features. Front Immunol 13:875093","journal-title":"Front Immunol"},{"key":"3418_CR54","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.lungcan.2022.03.008","volume":"166","author":"A Juarez-Garcia","year":"2022","unstructured":"Juarez-Garcia A et al (2022) Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer patients: a systematic literature review. Lung Cancer 166:205\u2013220","journal-title":"Lung Cancer"},{"key":"3418_CR55","doi-asserted-by":"crossref","first-page":"875488","DOI":"10.3389\/fimmu.2022.875488","volume":"13","author":"X Chu","year":"2022","unstructured":"Chu X et al (2022) The long-term and short-term efficacy of immunotherapy in non-small cell lung cancer patients with brain metastases: a systematic review and Meta-analysis. Front Immunol 13:875488","journal-title":"Front Immunol"},{"issue":"3","key":"3418_CR56","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00262-021-03017-z","volume":"71","author":"H Yu","year":"2022","unstructured":"Yu H et al (2022) Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer. Cancer Immunol Immunother 71(3):637\u2013644","journal-title":"Cancer Immunol Immunother"},{"key":"3418_CR57","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.wneu.2021.10.113","volume":"158","author":"K Brar","year":"2022","unstructured":"Brar K et al (2022) Comparative efficacy of treatments for Brain metastases from non-small cell lung cancer without an EGFR-Mutation\/ALK-Rearrangement: a systematic review and network meta-analysis. World Neurosurg 158:e87\u2013e102","journal-title":"World Neurosurg"},{"key":"3418_CR58","doi-asserted-by":"crossref","first-page":"175883592110185","DOI":"10.1177\/17588359211018537","volume":"13","author":"L Sheng","year":"2021","unstructured":"Sheng L et al (2021) Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis. Ther Adv Med Oncol 13:17588359211018537","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"3418_CR59","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","volume":"15","author":"M Wu","year":"2022","unstructured":"Wu M et al (2022) Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol 15(1):24","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3418_CR60","doi-asserted-by":"crossref","first-page":"11373","DOI":"10.1038\/s41598-017-11949-9","volume":"7","author":"D Fujimoto","year":"2017","unstructured":"Fujimoto D et al (2017) Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. Sci Rep 7(1):11373","journal-title":"Sci Rep"},{"issue":"11","key":"3418_CR61","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1016\/S1470-2045(18)30415-7","volume":"19","author":"S Kaasa","year":"2018","unstructured":"Kaasa S et al (2018) Integration of oncology and palliative care: a lancet oncology commission. Lancet Oncol 19(11):e588\u2013e653","journal-title":"Lancet Oncol"},{"issue":"27","key":"3418_CR62","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.2217\/fon-2020-0248","volume":"16","author":"YJ Kim","year":"2020","unstructured":"Kim YJ et al (2020) Real-world effectiveness of nivolumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Future Oncol 16(27):2045\u20132058","journal-title":"Future Oncol"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-025-03418-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-025-03418-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-025-03418-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T04:14:57Z","timestamp":1772079297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-025-03418-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3418"],"URL":"https:\/\/doi.org\/10.1007\/s10143-025-03418-z","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"5 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is deemed to exempt to received ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"253"}}